HOMA-IR blood test
Homeostatic model assessment of insulin resistance. Also called: HOMA, HOMA1-IR, Homeostasis model assessment
HOMA-IR estimates insulin resistance from one fasting blood draw: fasting insulin × fasting glucose ÷ 22.5 (÷ 405 in US glucose units). Higher means more insulin resistance. No lab or guideline sets a cut-off; studies put it at about 1.85 to 2.6.
At a glance
| What it measures | An estimate of insulin resistance from fasting insulin and fasting glucose taken at the same time. |
|---|---|
| Formula | Fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5; with glucose in mg/dL, divide by 405. |
| Cut-offs | No lab or guideline cut-off. Studies: about 2.6 (75th percentile, Spain 2003); 1.85 in non-diabetic men and 2.05 by metabolic-syndrome risk (Spain 2013). |
| Peptides that move it | Lowered by Tirzepatide, Retatrutide, Semaglutide and Survodutide in trials; no data for the growth hormone-releasing peptides. |
| Lab code | LOINC 47214-2; no lab reports it directly (order Labcorp 004333 or Quest 561 insulin with fasting glucose) |
What is HOMA-IR?
HOMA-IR (homeostatic model assessment of insulin resistance) turns a fasting insulin and a fasting glucose into one number. It comes from a model of the feedback loop between glucose and insulin, and it correlated well with the euglycaemic clamp, the reference method (Rs = 0.88). The higher the number, the more insulin the body needs to keep fasting glucose normal.
How it is made and regulated
Where it is made
HOMA-IR is not made by the body: it is calculated. Matthews and colleagues built a model of how fasting glucose and insulin settle into balance, and compared a person's fasting values with the model to estimate insulin resistance.
Sources: [1]
What controls it
Anything that raises insulin resistance raises HOMA-IR: the pancreas releases more insulin to hold glucose steady, and the product of the two rises. Insulin resistance is present in most people with impaired glucose tolerance or type 2 diabetes and in about 25% of non-obese people with normal glucose tolerance.
How it travels in the blood
The original 1985 model came with an approximate formula, which is what most labs and studies use; a computer version (HOMA2) exists but is used less. HOMA needs only a single fasting sample for insulin and glucose.
Sources: [2]
How long it lasts
HOMA-IR moves with fasting insulin and glucose. On treatment it can change within weeks: liraglutide improved it after 2 weeks, before any weight loss.
Sources: [4]
What it does
The estimate is imprecise for one person: its coefficient of variation is 31% for insulin resistance. Its developers recommend it mainly for cohort and population studies.
Reference ranges
No lab prints a HOMA-IR range and no guideline sets one. Cut-offs come from population studies and depend on the population, age and sex.
Gayoso-Diz 2013 (2459 adults, Spain)
| Group | Range (score) |
|---|---|
| 90th percentile of the population | 3.46 |
| Cut-off by metabolic-syndrome components | 2.05 |
| Non-diabetic men | 1.85 |
The authors note the threshold must be adjusted for age in non-diabetic women.
Ascaso 2003 (65 adults with normal glucose)
| Group | Range (score) |
|---|---|
| 75th percentile, used as the insulin-resistance cut-off | 2.6 |
Validated against an intravenous glucose tolerance test in adults with normal glucose metabolism.
These are study cut-offs from Spanish adults, not reference intervals; the threshold changes with age in women.
Units: HOMA-IR has no unit. It is fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5, or × fasting glucose (mg/dL) ÷ 405 with US glucose units. [5]
Is there an "optimal" range?
There is no agreed HOMA-IR cut-off; published thresholds differ by method and population.
About 2.6
2.6 (75th percentile)
Ascaso 2003
The 75th percentile in adults with normal glucose metabolism, validated against a glucose tolerance test.
Sources: [6]
Lower, by metabolic risk
1.85 to 2.05
Gayoso-Diz 2013
Using metabolic-syndrome components instead of a percentile lowers the cut-off from 3.46 to 2.05, and to 1.85 in non-diabetic men.
Sources: [5]
What raises it
| Factor | How | How much |
|---|---|---|
| Insulin resistance (obesity, impaired glucose tolerance, type 2 diabetes)Condition | Higher fasting insulin is needed to hold glucose steady. | No published magnitude [3] |
| Growth hormone therapyHormone | Growth hormone raised HOMA in adults with growth hormone deficiency. | Up to 2.7-fold at day 5 [7] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Weight loss on incretin drugsPeptide | Tirzepatide, Retatrutide and Semaglutide lowered HOMA-IR in trials, mostly through weight loss. | -51.2% vs -6.2% on placebo (tirzepatide, 52 weeks) [8] [9] [10] |
| IGF-1Peptide | Recombinant IGF-1 (Insulin-Like Growth Factor 1) lowered HOMA in a short study, the opposite of growth hormone. | 0.66 of baseline by day 2 [7] |
Peptides that affect HOMA-IR
How each peptide in our library changes HOMA-IR, from published trials. No FDA label reports HOMA-IR, so every row is a study; some report HOMA2-IR, the updated computer model, which is noted where it applies. No study has reported HOMA-IR after dosing Tesamorelin, CJC-1295, Ipamorelin, Sermorelin, Mod GRF 1-29, Hexarelin, GHRP-2, GHRP-6, MK-677 (Ibutamoren), MOTS-c, 5-Amino-1MQ or Lixisenatide on its own; PubMed searches for each with HOMA find no human dosing data (MOTS-c studies measure the body's own MOTS-c, and the GHRP-6 papers are rodent studies).
| Peptide | Effect on HOMA-IR | Size of effect | Evidence |
|---|---|---|---|
| Exenatide | Lowers | No figure in the abstract: in 174 adults with type 2 diabetes on metformin, adding exenatide 10 micrograms twice daily for 12 months lowered HOMA-IR more than adding placeboA year-long placebo-controlled trial found a greater HOMA-IR fall. [11] | Human trials |
| IGF-1 (Insulin-Like Growth Factor 1) | Lowers | 6 adults with growth hormone deficiency (crossover): HOMA fell to 0.66 of baseline by day 2 of a recombinant IGF-1 infusion, while growth hormone raised it up to 2.7-foldIGF-1 lowered HOMA, the opposite of growth hormone, in a small study. [7] | Human trials |
| Liraglutide | Lowers | No figure in an open source: in a 14-week randomized trial in adults with obesity and prediabetes, liraglutide improved HOMA-IR and HOMA2 after 2 weeks, before any weight lossImproved HOMA-IR within 2 weeks, ahead of weight loss. [4] | Human trials |
| Retatrutide | Lowers | Phase 2 substudy, 98 adults with obesity and liver fat of 10% or more, 48 weeks: HOMA2-IR -36.3% on 1 mg (not significant), -49.4% on 4 mg, -52.4% on 8 mg and -69.3% on 12 mg vs -11.1% on placeboThe largest HOMA2-IR falls of any peptide here, in one phase 2 substudy. [9] | Human trials |
| Semaglutide | Lowers | 2.4 mg, 68 weeks, adults with obesity and prediabetes: HOMA-IR 28% lower than placebo (STEP 1) and 29.7% lower (STEP 3). Adolescents with obesity: -35.0% vs -5.3% on placeboCut HOMA-IR by about a quarter to a third vs placebo in people with prediabetes or obesity. [10] [12] | Human trials |
| Survodutide | Lowers | No figure in the abstract: in two phase 2 trials (type 2 diabetes for 16 weeks; overweight or obesity), survodutide lowered HOMA-IR significantly vs placeboLower HOMA-IR in both trials, largely tracking weight loss. [13] | Human trials |
| Tirzepatide | Lowers | Adults with obesity and sleep apnea, 10 or 15 mg, 52 weeks: HOMA-IR -51.2% vs -6.2% on placebo without PAP therapy and -55.8% vs -2.7% with PAP. In type 2 diabetes (40 weeks), HOMA2-IR fell 15.5%-24.0% vs 5.1% on semaglutide 1 mgRoughly halved HOMA-IR in placebo-controlled trials; most, but not all, of the fall tracks weight loss. [8] [14] | Human trials |
| Dulaglutide | No clear effect | Measured, no clear change: 12-week open-label pilot in type 2 diabetes, HOMA-IR -0.19 on dulaglutide vs -1.71 on empagliflozin; only empagliflozin reduced it significantlyNo significant HOMA-IR change in one small pilot; dulaglutide improved beta-cell function instead. [15] | Human trials |
What high or low results can mean
A high result
A HOMA-IR above about 2 to 2.6 suggests insulin resistance in adult studies. It means the body needs more insulin than usual to keep fasting glucose normal.
- Obesity
- Impaired glucose tolerance or type 2 diabetes
- Growth hormone excess or therapy
A low result
A low HOMA-IR means good insulin sensitivity. With high glucose and low insulin, it can instead reflect too little insulin production.
- Good insulin sensitivity
- Low insulin production
How the test works
| Sample | Serum for insulin and plasma or serum for glucose, drawn at the same fasting visit. |
|---|---|
| Fasting | Both values must be fasting; Labcorp and Quest require a fasting sample for insulin. |
| Timing | No guideline recommends routine HOMA-IR testing; the ADA diagnoses diabetes with glucose and A1C. |
| Lab differences | HOMA-IR depends on the insulin assay, and insulin results differ between platforms, so values from different labs are not interchangeable. |
| Retesting | Compare results calculated from the same lab, and read changes against the 31% imprecision of a single estimate. |
| Labcorp order code | 004333: Insulin (with fasting glucose, for HOMA-IR) |
| Quest Diagnostics order code | 561: Insulin (with fasting glucose, for HOMA-IR) |
| LOINC codes |
|
History
HOMA turned a single fasting blood draw into an estimate of insulin resistance.
- 1985Matthews and colleagues publish the homeostasis model assessment and its approximate formula. [1]
- 2004The HOMA developers review its use and abuse and recommend it mainly for cohort and population studies. [2]
- 2013A study of 2459 Spanish adults shows HOMA-IR cut-offs shift with metabolic risk, age and sex. [5]
FAQ
How do I calculate HOMA-IR?
Multiply fasting insulin (µIU/mL) by fasting glucose (mmol/L) and divide by 22.5. With glucose in mg/dL, divide by 405 instead.
What is a normal HOMA-IR?
There is no lab or guideline range. Studies put the insulin-resistance cut-off at about 2.6 (75th percentile) or 1.85 to 2.05 by metabolic risk.
Can I order a HOMA-IR test?
Not as a single test at Labcorp or Quest. Order fasting insulin with fasting glucose and calculate it.
Is HOMA-IR accurate?
It correlates well with the clamp reference method (Rs = 0.88), but one result has a 31% coefficient of variation, so small changes are not meaningful.
Sources: [1]
What is the difference between HOMA-IR and HOMA2-IR?
HOMA-IR uses the original 1985 approximate formula; HOMA2 is the updated computer model. Some trials report one, some the other, so their numbers are not directly comparable.
Does the ADA use HOMA-IR?
No. The ADA diagnoses diabetes and prediabetes with glucose and A1C.
Sources: [16]
Does tirzepatide affect HOMA-IR?
Yes. In adults with obesity and sleep apnea, HOMA-IR fell 51.2% vs 6.2% on placebo over 52 weeks; in type 2 diabetes, HOMA2-IR fell 15.5%-24.0%.
Which peptides lower insulin resistance?
In trials, Tirzepatide, Retatrutide, Semaglutide, Survodutide, Liraglutide and Exenatide lowered HOMA-IR. Retatrutide 12 mg lowered HOMA2-IR 69.3% in a phase 2 substudy.
Do growth hormone peptides raise HOMA-IR?
There are no HOMA-IR studies of Tesamorelin, CJC-1295, Ipamorelin or MK-677 (Ibutamoren). Growth hormone itself raised HOMA up to 2.7-fold, while IGF-1 (Insulin-Like Growth Factor 1) lowered it.
Sources: [7]
What other insulin-resistance scores exist?
Labcorp's NMR LipoProfile reports LP-IR, a 0-100 score built from lipoprotein particles. It is a different calculation from HOMA-IR.
Sources: [20]
References
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. PMID 3899825
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. PMID 15161807
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. PMID 3056758
- Mashayekhi M, Nian H, Mayfield D, et al. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes. 2024;73(1):38-50. PMID 37874653
- Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47. PMID 24131857
- Ascaso JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26(12):3320-5. PMID 14633821
- Schmid C, Bianda T, Zwimpfer C, et al. Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels. Growth Horm IGF Res. 2005;15(4):300-3. PMID 16054413
- Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026;32(2):653-659. PMID 41540105
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID 38858523
- Perreault L, Davies M, Frias JP, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022;45(10):2396-2405. PMID 35724304
- Derosa G, Franzetti IG, Querci F, et al. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. Diabet Med. 2012;29(12):1515-23. PMID 22540883
- Arslanian S, Gies I, Goldman B, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. 2026;49(6):954-962. PMID 41296499
- Ekinci EI, Maldonado SG, Unseld A, et al. Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes Obes Metab. 2026;28(9):8242-8253. PMID 42331726
- Frias JP, De Block C, Brown K, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. 2024;109(7):1745-1753. PMID 38252888
- Jun JE, Oh DH, Jeong IK, et al. Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses. Front Endocrinol (Lausanne). 2026;17:1843595. PMID 42388875
- American Diabetes Association Professional Practice Committee for Diabetes* . 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S27-S49. PMID 41358893
- Labcorp. Test 004333: Insulin. Methodology, specimen, patient preparation, reference range, limitations and LOINC map. labcorp.com/tests/004333/insulin
- Quest Diagnostics. Test 561: Insulin. Test directory: methodology, specimen, patient preparation, LOINC and risk categories. testdirectory.questdiagnostics.com/test/test-detail/561/insulin?cc=PHP
- Larsen PB, Linneberg A, Hansen T, et al. Reference intervals for C-peptide and insulin derived from a general adult Danish population. Clin Biochem. 2017;50(7-8):408-413. PMID 27989491
- Labcorp. Test 884247: NMR LipoProfile With Lipids (Without Graph). Description of the Lipoprotein Insulin Resistance Index (LP-IR). labcorp.com/tests/884247/nmr-lipoprofile-with-lipids-without-graph
Educational information, not medical advice. Lab ranges and test codes were checked on November 2, 2026. Always use the range printed on your own report, and talk to a clinician about your results.